| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 14,182 | 28,866 | 1,262 | 1,750 |
| Cost of sales | 10 | 33 | 30 | 71 |
| Research and development | 18,757 | 15,747 | 15,303 | 25,780 |
| Selling, general and administrative, including stock-based compensation of 1,612, 1,341, 4,656 and 7,229 respectively | 7,602 | 9,350 | 11,608 | 39,592 |
| Total operating expenses | 26,369 | 25,130 | 26,941 | 65,443 |
| Loss from operations | -12,187 | 3,736 | -25,679 | -63,693 |
| Interest and other expense | 2,155 | 2,318 | 1,835 | 4,562 |
| Interest income and other | 1,573 | 1,834 | 2,219 | 3,444 |
| Net loss | -12,769 | 3,252 | -25,295 | -64,811 |
| Unrealized gain (loss) on investments | 43 | -39 | -94 | 542 |
| Comprehensive loss | -12,726 | 3,213 | -25,389 | -64,269 |
| Net loss per common share, basic (usd per share) | -0.04 | 0.01 | -0.07 | -0.18 |
| Net loss per common share, diluted (usd per share) | -0.04 | 0.01 | -0.07 | -0.18 |
| Weighted average common shares outstanding, basic (in shares) | 363,399,000 | 363,294,000 | 362,073,000 | 361,492,000 |
| Weighted average common shares outstanding, diluted (in shares) | 363,399,000 | 363,570,000 | 362,073,000 | 361,492,000 |
LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX)